EHA 2022 | The importance of venetoclax in newly diagnosed AML
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of venetoclax in patients with acute myeloid leukemia (AML) – including in different age groups, in the frontline and relapsed setting, as well as in combination with chemotherapy. Dr Kadia notes that venetoclax has become an important part of the treatment paradigm and further highlights combination approaches being investigated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme
